EGFR and non-small cell lung carcinoma: A subgroup analysis of the FLAURA trial (FLAURA), which demonstrated superiority of osimertinib over first generation EGFR-TKIs in advanced EGFR-mutated NSCLC, examined outcomes of 128 patients with CNS lesions.